ライフサイエンスコーパス: granulocyte

1 cells, and in 'immunological diseases' in MF granulocytes.

2 mesenchymal stem cells, endothelial cells or granulocytes.

3 f transendothelial migration of neutrophilic granulocytes.

4 ual loss of donor HSPCs and peripheral blood granulocytes.

5 entiation of AK2-deficient iPSCs into mature granulocytes.

6 CD63 and unique markers identifying basophil granulocytes.

7 meningeal macrophages, dendritic cells, and granulocytes.

8 , which, in turn, locally differentiate into granulocytes.

9 of infiltrating macrophages and neutrophilic granulocytes.

10 Moreover, selective granulocyte ablation in vivo impaired vascular and hemat

11 nal negative phenotypic correlations between granulocyte abundance and white matter integrity.

12 a monoclonal antibody to eliminate residual granulocyte activity.

13 Enhanced levels of platelet/granulocyte aggregates (PGAs) are found in patients suff

14 es marked by increased formation of platelet/granulocyte aggregates.

15 Neutrophil granulocytes, also called polymorphonuclear leukocytes (

16 iate proinflammatory effects in vivo, namely granulocyte and mast cell recruitment to the lungs.

17 Correlations between granulocyte and monocyte clonalities were greatest, foll

18 Granulocytes and B cells were also diminished in the bon

19 intestinal inflammation with accumulation of granulocytes and CD4+ T cells.

20 Manipulation of the cross-talk between granulocytes and endothelial cells may lead to new thera

21 Myeloperoxidase is expressed exclusively in granulocytes and immature myeloid cells and transforms t

22 cate that immune cells, including monocytes, granulocytes and lymphocytes, regulate metabolic homeost

23 tic stem cells constantly differentiate into granulocytes and macrophages via a distinct differentiat

24 ed that IgE specifically bound to basophilic granulocytes and mast cells through the Fc portion of th

25 g of Ly-6C/Ly-6G-specific VHH immunotoxin to granulocytes and monocytes, granulocytes were significan

26 tly, HSC-derived cells replace erythrocytes, granulocytes and monocytes.

27 Clinical parameters, activation of blood granulocytes and sputum characteristics were assessed in

28 tions of C/EBPepsilon fail to develop normal granulocytes and suffer from repeated infections.

29 , IL-10 signaling activation, recruitment of granulocytes, and accumulation of myeloid cells.

30 odeficiency affecting B cells and neutrophil granulocytes, and complex developmental aberrations, inc

31 ngths were normal in patient fibroblasts and granulocytes, and low normal in lymphocytes, which were

32 by myeloid cells, particularly macrophages, granulocytes, and myeloid dendritic cells (mDC).

33 the three major human DC subsets, monocytes, granulocytes, and NK and B cells.

34 to whole blood increases CD11b expression on granulocytes, and this increase is prevented by blockade

35 nature of leukocyte activation and increased granulocytes; and 4) decreased expression of lymphocyte

36 Based on studies in mouse tumor models, granulocytes appear to play a tumor-promoting role.

37 We show that granulocytes are produced in the bone marrow, released i

38 We demonstrate novel mechanisms of how granulocytes are recruited to the colon that may have th

39 Gene expression analyses indicated that granulocytes are the main source of the cytokine TNFalph

40 rm hematopoietic clonal output of monocytes, granulocytes, B cells, and T cells from a polyclonal poo

41 basophils initiate transmigration like other granulocytes but, upon activation via their high-affinit

42 ern has been described in maturing mammalian granulocytes, but it is unknown whether IR occurs broadl

43 was associated with toxicity against mature granulocytes, but not toward human hematopoietic progeni

44 as characterized by tissue infiltration with granulocytes, but reversed by re-expression of Triad1 in

45 However, production of the granulocyte chemoattractants CXCL8 and CCL11 was not ind

46 ylalanine allows Runx1 to increase Cebpa and granulocyte colony formation by Runx1-deleted murine mar

47 Granulocyte colony stimulating factor (G-CSF) may enhanc

48 gation of BSA, beta2-microglobulin (beta2m), granulocyte colony stimulating factor (G-CSF), and three

49 d neutrophil-activating protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocy

50 eraction chromatography of recombinant human granulocyte colony stimulating factor is demonstrated.

51 and exhibited significantly lower levels of granulocyte colony stimulating factor, IL-8, macrophage

52 3 ligand, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor (5 GFs) either alo

53 to the treatment when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administra

54 the stabilization of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against st

55 phil expansion and migration by antagonizing granulocyte colony-stimulating factor (G-CSF) and chemok

56 We assessed the safety and efficacy of granulocyte colony-stimulating factor (G-CSF) and haemop

57 Rgamma) produced severely reduced amounts of granulocyte colony-stimulating factor (G-CSF) and of nit

58 Finally, the concurrent administration of granulocyte colony-stimulating factor (G-CSF) enhanced R

59 The inherent disadvantages of using granulocyte colony-stimulating factor (G-CSF) for hemato

60 Granulocyte colony-stimulating factor (G-CSF) is a regul

61 Granulocyte colony-stimulating factor (G-CSF) is used cl

62 ocyte chemoattractive protein 1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) levels in

63 antithymocyte globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves

64 Purpose To describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxi

65 BM) to the blood circulation by the cytokine granulocyte colony-stimulating factor (G-CSF) through co

66 mononuclear cells (BMMC) and the ability of granulocyte colony-stimulating factor (G-CSF) to mobiliz

67 ulate MTA1 expression in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen

68 MIP-1beta, granulocyte colony-stimulating factor (G-CSF), interleuk

69 IL-15), IL-18, gamma interferon (IFN-gamma), granulocyte colony-stimulating factor (G-CSF), monocyte

70 ately 35% at 1 year after transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized

71 opulation that appears in the circulation of granulocyte colony-stimulating factor (G-CSF)-treated do

72 magnitude to a standard multi-day regimen of granulocyte colony-stimulating factor (G-CSF).

73 Human granulocyte colony-stimulating factor (GCSF) is a well-k

74 Human erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was indepe

75 was also associated with elevated levels of granulocyte colony-stimulating factor (P = .02).

76 nsivist-led service, meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed meli

77 of meropenem, and adjunctive treatment with granulocyte colony-stimulating factor in 1998.

78 gG deposits and the pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of

79 Reduction of neutrophil functions via granulocyte colony-stimulating factor neutralization sig

80 Filgrastim, an analog for granulocyte colony-stimulating factor produced by recomb

81 companied by mutations in CSF3R encoding the granulocyte colony-stimulating factor receptor (G-CSFR)

82 me high frequency recurrent mutations in the granulocyte colony-stimulating factor receptor gene CSF3

83 cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL)

84 of type I and II cytokine receptors, except granulocyte colony-stimulating factor receptor, which su

85 Restoring Cebpa expression by granulocyte colony-stimulating factor reverses the db ph

86 serum levels of IFN-gamma, IL-12, IL-6, and granulocyte colony-stimulating factor were significantly

87 d increased BAL fluid IL-1alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels

88 luid myeloperoxidase, IL-8, IL-1alpha, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels

89 reduced concentrations of interleukin-1beta, granulocyte colony-stimulating factor, and matrix metall

90 , soluble vascular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.

91 fts were mobilized with cyclophosphamide and granulocyte colony-stimulating factor, collected by peri

92 ta show that hematopoietic stress, including granulocyte colony-stimulating factor, do not increase t

93 d fluorouracil 750 mg/m2 IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks).

94 rotein-1, macrophage inflammatory protein-2, granulocyte colony-stimulating factor, keratinocyte chem

95 are (either fludarabine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus

96 n antibacterial cytokine response comprising granulocyte colony-stimulating factor, tumor necrosis fa

97 increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor-mobilized peripher

98 tation of primary functional human MEPs from granulocyte colony-stimulating factor-mobilized peripher

99 ct of a set of immune cells contained within granulocyte colony-stimulating factor-mobilized peripher

100 usion, tumor necrosis factor inhibitors, and granulocyte colony-stimulating factors.

101 he neuroprotective effects of the cytokines, granulocyte-colony stimulating factor (G-CSF) and stem c

102 ence coverage was obtained by reducing human granulocyte-colony stimulating factor (G-CSF) prior to M

103 Using a granulocyte-colony stimulating factor (G-CSF) receptor k

104 her key inflammatory factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL

105 kaemia (AML) samples, and downregulated upon granulocyte-colony stimulating factor (G-CSF)- mediated

106 aly in adulthood due to the up-regulation of granulocyte-colony stimulating factor (G-CSF); these eff

107 e primed macrophages in adulthood and raised granulocyte-colony stimulating factor and neutrophil cou

108 Neutralizing granulocyte-colony stimulating factor blocked susceptibi

109 nsplantation (HCT), either marrow (n = 4) or granulocyte-colony stimulating factor mobilized peripher

110 ministration of clofarabine, cytarabine, and granulocyte-colony stimulating factor priming.

111 The protein therapeutic granulocyte-colony stimulating factor was analyzed using

112 ulating levels of IL-1beta, IL-1alpha, IL-6, granulocyte-colony stimulating factor, granulocyte-macro

113 is, we identify the proinflammatory cytokine granulocyte-colony-stimulating factor (G-CSF or Csf-3) a

114 It involves subcutaneous injections of granulocyte-colony-stimulating factor/AMD3100 to mobiliz

115 formation of platelet-monocyte and platelet-granulocyte complexes.

116 onse to Schistocephalus infection, and their granulocytes constitutively generate threefold more reac

117 Mediator release from basophilic granulocytes correlated better with allergen levels per

118 creases in the clinical white blood cell and granulocyte count and is a well-documented effect of glu

119 anti-thymocyte globulin (ATG) and pegylated granulocyte CSF (G-CSF) would preserve beta cell functio

120 It was more efficient than granulocyte CSF (G-CSF), a common treatment of severe ne

121 on in stiffness alone is sufficient to cause granulocyte demargination.

122 eloid progenitors, which produce short-lived granulocytes, demonstrate that these are derived from ce

123 hyperresponsiveness was ameliorated using a granulocyte depletion Ab.

124 endritic cell differentiation while limiting granulocyte development.

125 tional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activatio

126 lon is a critical transcriptional factor for granulocyte differentiation and function.

127 orming unit-erythroid/CFU-erythroid, and CFU-granulocyte/erythroid/macrophage/MK) irrespective of the

128 y deregulating processes that normally limit granulocyte expansion during the innate immune response.

129 oneal saline stored a large number of mature granulocytes expressing a high level of Gr1 (Gr1(hi) cel

130 G-MDSCs, made of immature and mature granulocytes expressing high levels of degranulation mar

131 First, we found that the proportions of granulocytes from healthy human subjects that traversed

132 shown it to interfere with the maturation of granulocytes from immature precursors.

133 ssary for spontaneous NETosis of low-density granulocytes from individuals with systemic lupus erythe

134 in parallel using sorted mature and immature granulocytes from WT and C/EBPepsilon KO bone marrow.

135 Interestingly, Trem1, a gene critical to granulocyte function, was identified as a direct C/EBPep

136 ut sepsis and CD14(neg)CD15(pos) low-density granulocytes/granulocytic (G)-MDSCs were more specifical

137 In addition, immature granulocyte (IG) count, plasma cell-free DNA (cfDNA), an

138 le model using the activation state of blood granulocytes, (ii) compare its diagnostic value with spu

139 in depletion efficiency of monocytes versus granulocytes in mice.

140 long with an increase in the ratio of Gr1(+) granulocytes in peripheral white blood cells following b

141 row granulocyte reserve with an elevation of granulocytes in the circulation.

142 te responses that lead to an accumulation of granulocytes in the lungs.

143 Persistently elevated eosinophil granulocytes in the peripheral blood in children is chal

144 ated numbers of inflammatory macrophages and granulocytes in vivo.

145 ptide/beta-peptoid hybrid with monocytes and granulocytes indicating a cellular target expressed by t

146 r experiments, wild type, but not Tnfa(-/-), granulocytes induced vascular recovery, and wild-type gr

147 1R inhibitor with a CXCR2 antagonist blocked granulocyte infiltration of tumors and showed strong ant

148 rotein-coupled FPR2/ALXR in peripheral blood granulocytes isolated from HC subjects, children with IA

149 Monocytes/macrophages, but not granulocytes, isolated from experimental liver metastase

150 reduced NADPH oxidase function was found in granulocytes, leading to impaired NET formation.

151 CSF-3, originally defined as a regulator of granulocyte lineage development via its cell surface rec

152 precursor cell activation and commitment to granulocyte lineage development.

153 o instruct the lineage choice of uncommitted granulocyte M (GM) progenitors toward an M fate.

154 ophage colony-stimulating factor (M-CSF) and granulocyte-M-CSF (GM-CSF) and its implications for fluo

155 g factor (M-CSF; inflammation resolving) and granulocyte-M-CSF (GM-CSF; proinflammatory) may contribu

156 Conversely, granulocyte macrophage (GM)-CSFR had no effect on the mo

157 ng: tumor necrosis factor alpha (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF

158 cancer subjects treated with Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF

159 anulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF

160 day or 25 mg/m(2) per day) on days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mu

161 adermal vaccinations of IMA901 (4.13 mg) and granulocyte macrophage colony-stimulating factor (75 mug

162 rophage colony-stimulating factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF

163 Growing evidence shows that granulocyte macrophage colony-stimulating factor (GM-CSF

164 and clinical studies have demonstrated that granulocyte macrophage colony-stimulating factor (GM-CSF

165 In this context, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF

166 cial effectors of the interleukin-23 (IL-23)-granulocyte macrophage colony-stimulating factor (GM-CSF

167 langerin, when cultured with soluble ligands granulocyte macrophage colony-stimulating factor (GM-CSF

168 ectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF

169 d PuraMatrix(TM) peptide hydrogel containing granulocyte macrophage colony-stimulating factor (GM-CSF

170 genitors after coculture with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF

171 alpha, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hy

172 e evasion superfamily, to antagonize GM-CSF (granulocyte macrophage colony-stimulating factor) and IL

173 f numerous cytokines and chemokines, such as granulocyte macrophage colony-stimulating factor, interf

174 ma levels of tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor.

175 ared with all other treatments except CTLA-4/granulocyte macrophage colony-stimulating factor.

176 CSF, along with a hematopoietic shift toward granulocyte macrophage progenitor and myeloid cells.

177 ILC-driven colitis depends on production of granulocyte macrophage-colony stimulating factor (GM-CSF

178 sue, inflammation increased the secretion of granulocyte macrophage-colony stimulating factor, IL-12,

179 selective hypersensitivity of JMML cells to granulocyte macrophage-colony-stimulating factor (GM-CSF

180 the BM and spleen that are hypersensitive to granulocyte macrophage-CSF due to hyperactive RAS/ERK si

181 tic Ad co-expressing interleukin (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF

182 ia, and a characteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF

183 Granulocyte-macrophage colony-stimulating factor (GM-CSF

184 Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF

185 Granulocyte-macrophage colony-stimulating factor (GM-CSF

186 chanistic studies suggest that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF

187 PPAR-gamma), which is induced by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF

188 omyelitis and had reduced productions of the granulocyte-macrophage colony-stimulating factor (GM-CSF

189 production of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF

190 Granulocyte-macrophage colony-stimulating factor (GM-CSF

191 Granulocyte-macrophage colony-stimulating factor (GM-CSF

192 activity during SAA treatment or blockade of granulocyte-macrophage colony-stimulating factor (GM-CSF

193 s study, we tested the hypotheses that human granulocyte-macrophage colony-stimulating factor (GM-CSF

194 njections of neutralizing antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF

195 al M1-like MO, we tested the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF

196 Priming with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF

197 microbiota enhances respiratory defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF

198 We hypothesized that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF

199 nes/cytokines such as CCL-3 (MIP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF

200 hemokine (C-C motif) ligand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.

201 Using recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-C

202 gamma], interleukin 10 [IL-10], IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF

203 on of host genes coding for proinflammatory (granulocyte-macrophage colony-stimulating factor [GM-CSF

204 CD cases analyzed) had reduced responses to granulocyte-macrophage colony-stimulating factor and mar

205 (+) DCs acquired high langerin and CD1a with granulocyte-macrophage colony-stimulating factor and tra

206 Interferon-gamma and granulocyte-macrophage colony-stimulating factor are req

207 ardial AT and performed B-cell depletion and granulocyte-macrophage colony-stimulating factor blockad

208 Granulocyte-macrophage colony-stimulating factor is a po

209 B-cell depletion or granulocyte-macrophage colony-stimulating factor neutral

210 The combination of radiotherapy with granulocyte-macrophage colony-stimulating factor produce

211 related markers interferon-gamma, IL-15, and granulocyte-macrophage colony-stimulating factor protect

212 ith LNK deficiency to increase interleukin 3/granulocyte-macrophage colony-stimulating factor recepto

213 of intestinal lamina propria leukocytes with granulocyte-macrophage colony-stimulating factor resulte

214 nts with osteosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor with fi

215 ce of myeloid progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor with my

216 IL-6, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, and C-

217 terferon gamma, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gr

218 press more interleukin 17, interferon gamma, granulocyte-macrophage colony-stimulating factor, and tu

219 RB had reduced pSTAT5 after stimulation with granulocyte-macrophage colony-stimulating factor, compar

220 terleukin-6, interleukin-10, interleukin-17, granulocyte-macrophage colony-stimulating factor, interl

221 rs of this mutation had reduced responses to granulocyte-macrophage colony-stimulating factor, provid

222 that included the immunomodulatory adjuvants granulocyte-macrophage colony-stimulating factor, Toll-l

223 ctor-differentiated macrophages more than in granulocyte-macrophage colony-stimulating factor-differe

224 l clusters and 3-fold upregulated numbers of granulocyte-macrophage colony-stimulating factor-produci

225 Granulocyte-macrophage colony-stimulating factor-recepto

226 Granulocyte-macrophage colony-stimulating factor-recepto

227 s were isolated and expression of CSF2RB and granulocyte-macrophage colony-stimulating factor-respons

228 GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreti

229 nditioned to an alveolar-like phenotype with granulocyte-macrophage colony-stimulating factor.

230 V group had further enhancement of IL-10 and granulocyte-macrophage colony-stimulating factor.

231 tigen-1 and acquisition of responsiveness to granulocyte-macrophage colony-stimulating factor.

232 marked production of IFN-gamma, IL-17A, and granulocyte-macrophage colony-stimulating factor.

233 eron gamma, tumor necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor.

234 n disease pathogenesis and possibly also for granulocyte-macrophage colony-stimulating factor.

235 activation of the common beta subunit of the granulocyte-macrophage colony-stimulating factor/interle

236 Tumor-secreted TGF-beta and granulocyte-macrophage CSF (GM-CSF) enhanced the KDR/ID2

237 sociated with early lymphoid, erythroid, and granulocyte-macrophage differentiation.

238 iptional signatures of normal CD34(-) mature granulocyte-macrophage precursors, downstream of progeni

239 egakaryocyte-erythroid progenitor (MEP), and granulocyte-macrophage progenitor (GMP) cells, accompani

240 ypes through the same myeloid-restricted pre-granulocyte-macrophage progenitor (pre-GM) (Lin(-)Sca-1(

241 ol I transcription reduces both the leukemic granulocyte-macrophage progenitor and leukemia-initiatin

242 hil/macrophage lineage outputs from a common granulocyte-macrophage progenitor are still not complete

243 liteal lymphoid nodes, bone marrow cells and granulocyte-macrophage progenitor cells.

244 anscription factor critical for formation of granulocyte-macrophage progenitors (GMP) and leukemic GM

245 -primed multi-potential progenitors (LMPPs), granulocyte-macrophage progenitors (GMPs) and multi-lymp

246 uncover a unique spatiotemporal mechanism of granulocyte-macrophage progenitors (GMPs) employed in em

247 f the DC progenitors partially overlaps with granulocyte-macrophage progenitors (GMPs).

248 mmon myeloid progenitors committed to become granulocyte-macrophage progenitors and as megakaryocyte-

249 Runx1-deficient granulocyte-macrophage progenitors are characterized by

250 ng-term haematopoietic stem cells (HSCs) and granulocyte-macrophage progenitors compared with wild-ty

251 eage, bipotent megakaryocyte-erythrocyte and granulocyte-macrophage progenitors give rise to unipoten

252 human and mouse cardiac fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF

253 n [CAWS]), we identify an essential role for granulocyte/macrophage colony-stimulating factor (GM-CSF

254 Here we use imaging to track granulocyte/macrophage progenitor (GMP) behaviour in mic

255 kit(+) (LSK), common myeloid progenitor, and granulocyte/macrophage progenitor (GMP) cells.

256 ony-forming unit-megakaryocyte [CFU-MK], CFU-granulocyte/macrophage, burst-forming unit-erythroid/CFU

257 To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF

258 cells and Paneth cells, yet its function in granulocyte maturation has remained unknown.

259 ading to impaired progenitor maintenance and granulocyte maturation.

260 Here we show that alterations in granulocyte mechanical properties are the driving force

261 s producing interferon-gamma (IFN-gamma) and granulocyte monocyte colony stimulating factor (GM-CSF).

262 increased bone marrow Csf2ra expression and granulocyte monocyte precursors (GMPs), and protected fr

263 lavage eosinophils had more surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors

264 Granulocyte-monocyte progenitors (GMPs) and monocyte-den

265 d levels of proinflammatory cytokines, overt granulocyte/monocyte progenitor cell apoptosis, and fail

266 stical computation, to quantify the yield of granulocytes, monocytes, lymphocytes and three subsets o

267 Myeloid cells, including granulocytes, monocytes, macrophages, and dendritic cell

268 n glomerular IgG deposition and infiltrating granulocytes, much more severe glomerulonephritis, and a

269 e precursors (common myeloid progenitors and granulocyte myeloid precursors) in the bone marrow.

270 tion that is manifested by higher numbers of granulocytes, plasmablasts, and inflammatory Ly6C(hi) CC

271 environment, to the postnatal state wherein granulocytes predominate to provide innate immunity.

272 Adoptive transfer of BM, but not peripheral, granulocytes prevented the death of mice transplanted wi

273 In this study, we found aberrantly sustained granulocyte production in Icsbp(-/-) mice after stimulat

274 elective expansion of newly defined IRF8(lo) granulocyte progenitors (GPs); 2) tumor-derived GPs had

275 se in monocyte progenitors and a decrease in granulocyte progenitors among GMP cells.

276 nd ex vivo coculture with pericardial AT and granulocyte progenitors.

277 HSC)-enriched LSK population but not myeloid-granulocyte progenitors.

278 by delivering TNFalpha to endothelial cells, granulocytes promote blood vessel growth and hematopoiet

279 cells during inflammation and to facilitate granulocyte recruitment into the tissues.

280 osstalk and triggered a profound increase in granulocyte recruitment to tumors.

281 duced microglial proliferation, and impaired granulocyte recruitment with an earlier spread of pneumo

282 cells, resulting in reduction of the marrow granulocyte reserve with an elevation of granulocytes in

283 y uninfected population initiated a stronger granulocyte response to Schistocephalus infection, and t

284 ells caused HDAC2-mediated downregulation of granulocyte-specific chemokine expression in CAF, which

285 lular cortical actin, significantly reducing granulocyte stiffness, as measured with atomic force mic

286 Hence, we present evidence that granulocyte subsets can be distinguished by their differ

287 rived suppressor cells, dendritic cells, and granulocytes than control mice with AP.

288 ubiquitin ligase Triad1 is greater in mature granulocytes than in myeloid progenitor cells.

289 h shared more overlap with other circulating granulocytes than with mast cells.

290 Eosinophils are a subset of granulocytes that can be involved in the pathogenesis of

291 -CSF treatment generates low-density splenic granulocytes that inhibit experimental aGVHD.

292 Propensity of isolated polymorhonuclear granulocytes to form neutrophil extracellular traps (NET

293 ples, to assess the recruitment of ILC2s and granulocytes to the upper airways of subjects with atopy

294 are major sources of chemokines that recruit granulocytes to tumors.

295 tes induced vascular recovery, and wild-type granulocyte transfer did not prevent death or promote va

296 MCs (vector copy number [VCN] = 0.1-2.6) and granulocytes (VCN = 0.01-0.3) through the most recent vi

297 Granulocytes were consistently increased, dysplastic, an

298 H immunotoxin to granulocytes and monocytes, granulocytes were significantly more sensitive than mono

299 DNI) is the fraction of circulating immature granulocytes, which reflects severe bacterial infections

300 ast cells and IgE and basophils (circulating granulocytes, whose functions partially overlap with tho